Mounjaro Injection Pen – 12.5 mg (Tirzepatide)

Injection Pen – 12.5 mg Mounjaro (Tirzepatide) contains tirzepatide, a next-generation medication developed to help regulate blood sugar levels and support weight management. Tirzepatide works by mimicking two natural gut hormones—GLP-1 and GIP—that influence appetite, insulin secretion, and digestion.

This dual-hormone mechanism helps the body respond more effectively to food intake by stimulating insulin when needed, reducing excess glucose production by the liver, and slowing gastric emptying. As a result, users often experience improved glycemic control and reduced appetite, which can support gradual weight loss.

Each injection pen is pre-filled for convenience and designed for once-weekly subcutaneous administration, typically into the abdomen, thigh, or upper arm

Supports blood sugar control
Tirzepatide helps regulate glucose levels by enhancing insulin release and reducing glucose production in the liver.

Promotes weight management
By reducing appetite and slowing digestion, it helps users feel fuller longer and consume fewer calories.

Dual-hormone mechanism
Unlike many traditional therapies, tirzepatide activates both GLP-1 and GIP receptors for enhanced metabolic support.

Convenient once-weekly dosing
The pre-filled injection pen allows for easy self-administration once per week.

Supports long-term metabolic health
Improved insulin sensitivity and reduced appetite can contribute to better metabolic balance over time.

Injection Pen – 12.5 mg Mounjaro (Tirzepatide) is administered as a subcutaneous injection once per week. The injection can be given in the abdomen, thigh, or upper arm.

General usage guidelines:

• Use the injection on the same day each week for consistent results.

• Administer at any time of day, with or without meals.

• Follow a gradual dosing plan as recommended by a healthcare professional.

• Combine treatment with a healthy diet and regular physical activity for optimal results.

• Ensure proper training on using the injection pen before self-administration.

Patients should always follow the dosing schedule recommended by their healthcare provider.

Injection Pen – 12.5 mg Mounjaro (Tirzepatide) should be used under the guidance of a qualified healthcare professional.

Important precautions:

• Common side effects may include nausea, vomiting, diarrhea, decreased appetite, or abdominal discomfort.

• Inform your healthcare provider about any existing medical conditions before starting treatment.

• Do not use if you are allergic to tirzepatide or any of the product ingredients.

• Individuals with certain thyroid conditions should consult their doctor before use.

• Always follow proper storage instructions and keep the injection pen refrigerated until use.

If you experience severe side effects or allergic reactions, discontinue use and seek medical advice immediately.